Jointechlabs, Inc.

Jointechlabs, Inc. is a promising player in the field of regenerative medicine, offering innovative point-of-care therapies. With the FDA-cleared MiniTC® and the pending CE Mark for the Mini-Stem System™, JTL is poised to make a significant impact. Their devices empower healthcare practitioners and hospitals to administer safe, cost-effective regenerative treatments without requiring major infrastructure changes. Notably, both the MiniTC™ and Mini-Stem System™ serve as standalone devices and as platforms for developing clinical therapies and 3D bioprinting of tissues. Founded in 2014 in the United States, the company recently secured a $250.00K Series A investment on October 7, 2022, with Newchip Accelerator as the lead investor. This injection of funds positions JTL for further growth and development in the biotechnology and healthcare sectors.